¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"Acute gastroenteropathy due to Norwalk agent"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 3 ÆäÀÌÁö: 2
¿µ¹® acute cholecystitis ÇÑ±Û ±Þ¼º¾µ°³¿°
¼³¸í   
  º¸Åë ¾µ°³ ÃⱸÀÇ Æó»ö¿¡ ÀÇÇÑ °ÍÀ̸ç, ¿°ÁõÀÇ Á¤µµ´Â °æµµÀÇ ºÎÁ¾À¸·ÎºÎÅÍ ±«Àú¿Í Ãµ°øÀ» ¼ö¹ÝÇϴ °¨¿°Áõ±îÁö ÀÖ´Ù.
¿µ¹® severe acute respiratory syndrome(SARS) ÇÑ±Û »ç½º
¼³¸í   
  Áß±¹ ±¤µ¿ Áö¿ª¿¡¼­ °¡Àå ¸ÕÀú ¹ß»ýÇÑ Àü¿°¼º È£Èí±â ÁúȯÀ¸·Î ¼¼°èº¸°Ç±â±¸(WHO)¿¡¼­ ¡®ÁßÁõ±Þ¼ºÈ£ÈíÁõÈıº(SARS)'À¸·Î ¸í¸íÇß´Ù. ¼·¾¾ 38µµ ÀÌ»óÀÇ °í¿­°ú ±âħ, È£Èí°ï¶õ, Àú»ê¼ÒÁõ, X¼±»óÀÇ Æó·ÅÁõ»ó Áß Çϳª ÀÌ»óÀÇ Áõ»óÀÌ ³ªÅ¸³ª¸ç, µÎÅë, ±ÙÀ°Åë, ½Ä¿åºÎÁø, ÇǷΰ¨, ¹ßÁø, ¼³»ç¸¦ µ¿¹ÝÇÒ ¼ö ÀÖ´Ù. Ãʱâ Áõ»óÀº °¨±â¿Í ºñ½ÁÇÏÁö¸¸ Æó·ÅÀ¸·Î ¹ßÀüÇϸé Ä¡¸íÀûÀÏ ¼ö ÀÖ´Ù. ÇöÀç ¹àÇôÁø °¨¿°°æ·Î´Â È¯ÀÚ°¡ Àçä±â³ª ±âħÇÒ ¶§ ³»»Õ´Â Ä§¹æ¿ïÀ̰í, À̰ÍÀÌ ´Ù¸¥ »ç¶÷ÀǠȣÈí±â·Î µé¾î°¥ ¶§ Àü¿°µÈ´Ù. Ä§¹æ¿ïÀÌ Àü´ÞµÇ´Â °Å¸®´Â º¸Åë 1m·Î º¸°í ÀÖ´Ù. °ø±â¸¦ ÅëÇØ Àü¿°ÀÌ °¡´ÉÇϴٴ ÁÖÀåÀÌ Á¦±âµÆÁö¸¸ ¾ÆÁ÷ È®ÀεÇÁö ¾Ê¾Ò´Ù. ¿øÀαÕÀº º¯Á¾ Äڷγª¹ÙÀÌ·¯½º·Î ¹àÇôÁ³´Ù. 
  
  
¿µ¹® severe acute respiratory syndrome(SARS) ÇÑ±Û ÁßÁõ±Þ¼ºÈ£ÈíÁõÈıº
¼³¸í   
  Áß±¹ ±¤µ¿ Áö¿ª¿¡¼­ °¡Àå ¸ÕÀú ¹ß»ýÇÑ Àü¿°¼ºÈ£Èí±âº´À¸·Î ¼¼°èº¸°Ç±â±¸(WHO)¿¡¼­ ¡®ÁßÁõ±Þ¼ºÈ£ÈíÁõÈıº(SARS)'À¸·Î ¸í¸íÇß´Ù. ¼·¾¾ 38µµ ÀÌ»óÀÇ °í¿­°ú ±âħ, È£Èí°ï¶õ, Àú»ê¼ÒÁõ, X¼±»óÀÇ Æó·ÅÁõ»ó Áß Çϳª ÀÌ»óÀÇ Áõ»óÀÌ ³ªÅ¸³ª¸ç, µÎÅë, ±ÙÀ°Åë, ½Ä¿åºÎÁø, ÇǷΰ¨, ¹ßÁø, ¼³»ç¸¦ µ¿¹ÝÇÒ ¼ö ÀÖ´Ù. Ãʱâ Áõ»óÀº °¨±â¿Í ºñ½ÁÇÏÁö¸¸ Æó·ÅÀ¸·Î ¹ßÀüÇϸé Ä¡¸íÀûÀÏ ¼ö ÀÖ´Ù. ÇöÀç ¹àÇôÁø °¨¿°°æ·Î´Â È¯ÀÚ°¡ Àçä±â³ª ±âħÇÒ ¶§ ³»»Õ´Â Ä§¹æ¿ïÀ̰í, À̰ÍÀÌ ´Ù¸¥ »ç¶÷ÀǠȣÈí±â·Î µé¾î°¥ ¶§ Àü¿°µÈ´Ù. Ä§¹æ¿ïÀÌ Àü´ÞµÇ´Â °Å¸®´Â º¸Åë 1m·Î º¸°í ÀÖ´Ù. °ø±â¸¦ ÅëÇØ Àü¿°ÀÌ °¡´ÉÇϴٴ ÁÖÀåÀÌ Á¦±âµÆÁö¸¸ ¾ÆÁ÷ È®ÀεÇÁö ¾Ê¾Ò´Ù. ¿øÀαÕÀº º¯Á¾ Äڷγª¹ÙÀÌ·¯½º·Î ¹àÇôÁ³´Ù.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • acute fulminating meningococcemia
    ±Þ¼ºÀü°Ý¼ö¸·¾Ë±ÕÇ÷Áõ
  • acute hemolytic transfusion reaction
    ±Þ¼º¿ëÇ÷¼º¼öÇ÷¹ÝÀÀ
  • acute hepatitis
    ±Þ¼º°£¿°
  • acute idiopathic polyneuritis
    ±Þ¼ºÆ¯¹ß¿©·¯½Å°æ¿°, ±Þ¼ºÆ¯¹ß´Ù¹ß½Å°æ¿°
  • acute intermittent porphyria
    ±Þ¼º°£ÇæÆ÷¸£ÇǸ°Áõ
  • acute ischemic brachial neuropathy
    ±Þ¼ºÇãÇ÷À§ÆÈ½Å°æº´(Áõ), ±Þ¼ºÇãÇ÷»ó¿Ï½Å°æº´(Áõ)
  • acute lichenoid pityriasis
    ±Þ¼ºÅ¼±¸ð¾çÀܺñ´ÃÁõ
  • acute lymphocytic leukemia
    ±Þ¼º¸²ÇÁ±¸¹éÇ÷º´
  • acute myelocytic leukemia
    ±Þ¼º°ñ¼ö¼¼Æ÷¹éÇ÷º´
  • acute necrotizing hemorrhagic encephalopathy
    ±Þ¼º±«»çÃâÇ÷³úº´(Áõ)
  • acute necrotizing retinitis
    ±Þ¼º±«»ç¸Á¸·¿°
  • acute necrotizing ulcerative gingivitis
    ±Þ¼º±«»ç±Ë¾çÀÕ¸ö¿°, ±Þ¼º±«»ç±Ë¾çÄ¡Àº¿°
  • acute nephritis
    ±Þ¼ºÄáÆÏ¿°, ±Þ¼º½ÅÀå¿°
  • acute obliterating bronchiolitis
    ±Þ¼ºÆó¼â¼¼±â°üÁö¿°
  • acute pancreatitis
    ±Þ¼ºÀÌÀÚ¿°, ±Þ¼ºÃéÀå¿°
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • tocolytic agent
    ÀڱüöÃà¾ïÁ¦Á¦
  • toxic agent
    µ¶¹°, µ¶±Ø¹°
  • acute
    ±Þ¼º-
  • acute appendicitis
    ±Þ¼º¸·Ã¢ÀÚ²¿¸®¿°
  • acute pulmonary atelectasis
    ±Þ¼º¹«±âÆó
  • acute abdomen
    ±Þ¼ºº¹Áõ
  • acute cholecystitis
    ±Þ¼º¾µ°³¿°
  • acute acalculous cholecystitis
    ±Þ¼º¹«°á¼®¾µ°³¿°
  • acute emphysematous cholecystitis
    ±Þ¼º°ø±âÁõ¾µ°³¿°, ±Þ¼º°ø±âÁõ´ã³¶¿°
  • acute febrile episode
    ±Þ¼º¿­¼º¹ÝÀÀ
  • acute renal failure
    ±Þ¼ºÄáÆÏ±â´É»ó½Ç, ±Þ¼º½ÅºÎÀü(Áõ)
  • acute hepatitis
    ±Þ¼º°£¿°
  • acute transverse myelitis
    ±Þ¼ºÈ¾´Üô¼ö¿°
  • acute nephritis
    ±Þ¼ºÄáÆÏ¿°
  • acute ischemic brachial neuropathy
    ±Þ¼ºÇãÇ÷À§ÆÈ½Å°æº´Áõ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • acute intermittent porphyria
    ±Þ¼º°£ÇæÆ÷¸£ÇǸ°Áõ
  • acute lichenoid pityriasis
    ±Þ¼ºÅ¼±¸ð¾çÀܺñ´ÃÁõ
  • acute necrotizing retinitis
    ±Þ¼º±«»ç¸Á¸·¿°
  • acute normal tissue effect
    Á¤»óÁ¶Á÷±Þ¼º¿µÇâ
  • acute obliterating bronchiolitis
    ±Þ¼ºÆó¼â¼¼±â°üÁö¿°
  • acute phase reactant
    ±Þ¼º±â¹ÝÀÀ¹°Áú
  • acute phase reaction
    ±Þ¼º±â¹ÝÀÀ
  • acute phase serum
    ±Þ¼º±âÇ÷û
  • acute posterior ganglionitis
    (¢¡herpes zoster) ´ë»óÆ÷Áø, ¶ìÇ츣Æä½º
  • acute purulent sinusitis
    ±Þ¼º°í¸§ÄÚ°ç±¼¿°, ±Þ¼ºÈ­³óºÎºñµ¿¿°
  • acute radiation sickness
    ±Þ¼º¹æ»ç¼±º´
  • acute radiation syndrome
    ±Þ¼º¹æ»ç¼±ÁõÈıº
  • acute schizophrenic episode
    ±Þ¼ºÁ¤½ÅºÐ¿­º´»ðÈ­
  • acute situational stress reaction
    ±Þ¼º»óȲ½ºÆ®·¹½º¹ÝÀÀ
  • acute spasmodic laryngitis
    ±Þ¼º°æÁ÷Èĵο°
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • anorexiant =anorectic agent
    ½Ä¿å°¨ÅðÁ¦(ãÝé¯Êõ÷Üð¥), ½Ä¿å¾ïÁ¦Á¦.
  • anorexigenic agent
    ½Ä¿å¾ïÁ¦Á¦.
  • anti-inflammatory agent
    Ç׿°Áõ¾à(ù÷æúñøå·).
  • antiallergic agent
    Ç׾˷¹¸£±â¾à.
  • antiallergic agent =a. drug
    Ç׾˷¹¸£±â¾à.
  • antianticholinesterase agent
    Ç×-Ç×Äݸ°¿¡½ºÅ×¶ó¾ÆÁ¦.
  • antiarrhythmic agent
    Ç׺ÎÁ¤¸ÆÁ¦<¾à>.
  • antiarrhythmic agent =a. drug
    Ç׺ÎÁ¤¸ÆÁ¦<¾à>.
  • antiasthmatic agent =antasthmatic
    Ç×õ½Ä¾à(ù÷ô·ãÓå·).
  • antibacterial agent
    Ç×»ýÁ¦
  • antibacterial agent
    Ç×±Õ¾à(ù÷жå·), Ç×±Õ¹°Áú(ù÷жڪòõ), Ç×±ÕÁ¦(ù÷жð¥).
  • antibacterial agent
    Ç×±Õ¾à(ù÷жå·), Ç×±Õ¹°Áú, Ç×±ÕÁ¦.
  • anticariogenic agent
    1. Ç׿ì½Ä¼º ¾à<¹°Áú>(ù÷ó»ãÚàõå·<Úªòõ>). 2. Ç׿ì½Ä¼ºÀÎÀÚ.
  • anticholinergic agent
    Ç×Äݸ°Á¦
  • antifoaming agent =defoaming a.
    ¼ÒÆ÷Á¦(á¼øÜð¥).
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • agent
    ¾à¹°<Á¦>, ÀÛ¿ë¹°Áú(íÂéÄÚªòõ), º´ÀÎ(Ü»ì×).
  • agent, etiologic
    ¿øÀÎü
  • agent, infectious
    °¨¿°Ã¼, °¨¿°¿ø
  • agent, mutagenic
    µ¹¿¬º¯ÀÌ¿ø
  • alkylating agent
    ¾ËųȭÁ¦, ¾Ëųȭ¾à¹°.
  • alkylating agent
    ¾Ëųȭ ¾à¹°(¡­ûù å·Úª), ¾ËųȭÁ¦(¡­ûùð¥)
  • alkylating agent =a. drug
    ¾ËųȭÁ¦(ð¥).
  • alpha-sympathomimetic agent
    ¾ËÆÄ±³°¨½Å°æÀ¯»çÀÛ¿ëÁ¦
  • anesthetic agent
    ¸¶Ãë¾à, ¸¶ÃëÁ¦.
  • anorectic agent
    ½Ä¿å°¨ÅðÁ¦(ãÝé¯Êõ÷Üð¥).
  • anorexiant =anorectic agent
    ½Ä¿å°¨ÅðÁ¦(ãÝé¯Êõ÷Üð¥), ½Ä¿å¾ïÁ¦Á¦.
  • anorexigenic agent
    ½Ä¿å¾ïÁ¦Á¦.
  • anti-inflammatory agent
    Ç׿°Áõ¾à(ù÷æúñøå·).
  • antiallergic agent
    Ç׾˷¹¸£±â¾à.
  • antiallergic agent =a. drug
    Ç׾˷¹¸£±â¾à.
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • cytostatic agent
    ¼¼Æ÷Áõ½Ä¾ïÁ¦Á¦(á¬øàñòãÖåäð¤ð¥)
  • denaturing agent
    º¯¼ºÁ¦(ܨàõð¥)
  • eluting agent
    ¿ë¸®Á¦(éÁ×îð¥)
  • emulsifying agent
    ¿¡¸ÖÁ¯È­Á¦(ûùð¥)
  • F agent
    F Á¦(ð¥)
  • fusogenic agent
    À¶ÇÕ »ý¼ºÁ¦(ë×ùêßæà÷ð¥)
  • germicidal agent
    »ì±ÕÁ¦(߯жð¥)
  • immunosuppressive agent
    ¸é¿ª¾ï¾ÐÁ¦(Øóæ¹åääâð¥)
  • lipotropic agent
    ÁöÁúµ¿¿øÁ¦(ò·òõÔÑê¬ð¥)
  • lympholytic agent
    ¸²ÇÁ±¸¿ëÇØÁ¦(éÁú°ð­)
  • lysosomotropic agent
    ¶óÀ̼ÒÁ»ÀÚ±ØÁ¦(í©Ð»ð¥)
  • methylating agent
    ¸ÞƿȭÁ¦(ð¥)
  • mutagenic agent
    º¯ÀÌ¿øÁ¦(ܨì¶ê«ð¥)
  • oxidizing agent
    »êÈ­Á¦(ß«ûùð¥)
  • precipitating agent
    ħ°­Á¦(öØË½ð¥)
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 10 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • etiologic agent
    º´ÀÎü
  • gadolinium based contrast agent
    °¡µ¹¸®´½Á¶¿µÁ¦
  • immunosuppressive agent
    ¸é¿ª¾ïÁ¦¾à, ¸é¿ª¾ïÁ¦ÀÎÀÚ
  • paramagnetic agent
    »óÀÚ¼ºÁ¦Àç
  • protective agent
    º¸È£¾à, ÇÇÆ÷¾à
  • radioopaque agent
    ¹æ»ç¼±ºñÅõ°ú¼ºÁ¦Àç
  • radioprotective agent
    ¹æ»ç¼±¹æÈ£Á¦
  • sclerosing agent
    °æÈ­¾à
  • therapeutic agent
    Ä¡·á¾à
  • thrombolytic agent
    Ç÷Àü¿ëÇØ¾à
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
d/t due to
dt due to; dystonic
DUE drug use evaluation
EDD effective drug duration; electron dense deposit; end-diastolic dimension; esophageal detection devic...
HSAS hydrocephalus due to stenosis of aqueduct of Sylvius; hypertrophic subaortic stenosis
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
CAA Chicken anaemia agent
FWA fluorescent whitening agent
NMBA Neuromuscular blocking agent
SMA Snow Mountain Agent
UCA ultrasound contrast agent
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • antiallergic agent
    Ç׾˷¹¸£±â ¾à
  • anticariogenic agent
    Ç׿ì½Ä¼º ¾à, Ç׿ì½Ä¼º ÀÎÀÚ
    ¿ì½Ä ¿¹¹æ¿¡ È¿°ú°¡ ÀÖ´Â ¾àÁ¦.
  • antifibrinolytic agent
    Ç×¼¶À¯¼Ò ¿ëÇØÁ¦
  • antifoaming agent
    ¼ÒÆ÷Á¦
    µ¿ÀǾî=defoaming.
  • antifungal agent
    Ç×Áø±Õ ¾à, Ç×Áø±Õ ¹°Áú, Ç×Áø±Õ ÀÎÀÚ, Ç×°õÆÎÀÌ ¾à
  • antineoplastic agent
    Ç×Á¾¾çÁ¦
  • antiparasympathetic agent
    Ç׺α³°¨½Å°æ, Ç׺α³°¨½Å°æ¼º
  • antitubercular agent
    Ç×°áÇÙÁ¦
  • antituberculous agent
    Ç×°áÇÙ ¾à
  • antitumor agent
    Ç׾Ͼà, Á¦¾Ï ¾à, Ç×Á¾¾ç ¾à, Ç×Á¾¾ç¼º ¾à, Ç×Á¾¾ç ÀÎÀÚ, Ç×Á¾¾ç¼º ÀÎÀÚ
  • autonomic blocking agent
    ÀÚÀ² ½Å°æ Â÷´ÜÁ¦
  • beta-adrenergic blocking agent
    º£Å¸ ¾Æµå·¹³¯¸°¼º Â÷´ÜÁ¦
  • bleaching agent
    Ç¥¹éÁ¦
    ¿°·á³ª »ö±òÀ» »©³»´Â È­ÇÐÀû ¾àÁ¦.
  • bonding agent
    °áÇÕÁ¦, Á¢ÂøÁ¦, º»µùÁ¦
    Ä¡Áú°ú ÇÇÁ¢ÀÛ¹°°úÀÇ »çÀÌ¿¡ °³Àç½ÃÄÑ, ¾çÀÚ¸¦ Á¢ÇÕ½ÃŰ´Â Á¢ÇÕÁ¦.
  • buffering agent
    ¿ÏÃæÁ¦
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
alpha-adrenergic blocking agent An agent that competitively blocks alpha-adrenergic receptors; used in the treatment of hypertension.
Synonym: alpha-blocker.
(05 Mar 2000)
antianxiety agent A functional category of drugs useful in the treatment of anxiety and able to reduce anxiety at doses which do not cause excessive sedation (e.g., diazepam).
Synonym: anxiolytic, minor tranquilliser.
(05 Mar 2000)
antidiabetic agent A substance that helps a person with diabetes control the level of glucose (sugar) in the blood so that the body works as it should. See: insulin.
(09 Oct 1997)
antifibrinolytic agent Agents that prevent fibrinolysis or lysis of a blood clot or thrombus. Several endogenous antiplasmins are known. The drugs are used to control massive haemorrhage and in other coagulation disorders.
(12 Dec 1998)
antifoam agent A chemical that reduces the surface tension of foams that form on thesurface of broths in fermentors because of aeration or agitation. Stearyldecanol, octal decanol, vegetable oils, silicones, sulphonates, andpolypropylene glycol are typically used, though they can cause problems inrefining the broth later on.
(09 Oct 1997)
anti-inflammatory agent Agents that counteract or suppress the inflammatory process. An antirheumatic agent or inflammation mediator, both endogenous and exogenous substances used to counteract the inflammatory process or alleviate or prevent rheumatic diseases, and the compounds that mediate the inflammation process.
(12 Dec 1998)
anti-inflammatory agent, non-steroidal Anti-inflammatory agents that are not steroids. In addition to anti-inflammatory actions, they have analgesic, antipyretic, and platelet-inhibitory actions. They are used primarily in the treatment of chronic arthritic conditions and certain soft tissue disorders associated with pain and inflammation. They act by blocking the synthesis of prostaglandins by inhibiting cyclooxygenase, which converts arachidonic acid to cyclic endoperoxides, precursors of prostaglandins. Inhibition of prostaglandin synthesis accounts for their analgesic, antipyretic, and platelet-inhibitory actions; other mechanisms may contribute to their anti-inflammatory effects. Certain nsaids also may inhibit lipoxygenase enzymes or phospholipase c or may modulate T-cell function. (ama drug evaluations annual, 1994, p 1814-5)
(12 Dec 1998)
anti-inflammatory agent, steroidal Steroidal agents capable of suppressing or counteracting the inflammatory process by acting on body mechanisms, without directly antagonizing the causative agents.
(12 Dec 1998)
anti-inflammatory agent, topical Anti-inflammatory agent that are applied to the skin and whose pharmacological effect only occurs at the area of application.
(12 Dec 1998)
antinematodal agent Substances used in the treatment or control of nematode infestations. They are used also in veterinary practice.
(12 Dec 1998)
antineoplastic agent Agents inhibiting or preventing the growth of neoplasms, checking the maturation and proliferation of malignant cells.
(12 Dec 1998)
antineoplastic agent, alkylating A class of drugs that differs from other alkylating agents used clinically in that they are monofunctional and thus unable to cross-link cellular macromolecules. Among their common properties are a requirement for metabolic activation to intermediates with antitumour efficacy and the presence in their chemical structures of n-methyl groups, that after metabolism, can covalently modify cellular DNA. The precise mechanisms by which each of these drugs acts to kill tumour cells are not completely understood.
(12 Dec 1998)
antineoplastic agent, combined The use of two or more chemicals simultaneously or sequentially in the drug therapy of neoplasms. The drugs need not be in the same dosage form.
(12 Dec 1998)
antineoplastic agent, hormonal Antineoplastic agent that are used to treat hormone-sensitive tumours. Hormone-sensitive tumours may be hormone-dependent, hormone-responsive, or both. A hormone-dependent tumour regresses on removal of the hormonal stimulus, by surgery or pharmacological block. Hormone-responsive tumours may regress when pharmacologic amounts of hormones are administered regardless of whether previous signs of hormone sensitivity were observed. The major hormone-responsive cancers include carcinomas of the breast, prostate, and endometrium; lymphomas; and certain leukaemias.
(12 Dec 1998)
antineoplastic agent, phytogenic Agents, obtained from higher plants that have demonstrable cytostatic or antineoplastic activity.
(12 Dec 1998)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • commission agent
    °Å°£²Û;Á߸ÅÀÎ;»ç¼³ ¸¶±ÇÀå¼ö
  • consular agent
    ¿µ»ç ´ë¸®
  • contact agent
    Ã˸Å;Á¢ÃËÁ¦(catalyzer)
  • conversion agent
    Àüȯ ´ë¸® ±â°ü
  • county agent
    (¿¬¹æ.ÁÖÁ¤ºÎ°¡ ÆÄ°ßÇÑ)³ó»ç °í¹®
  • double agent
    ÀÌÁß °£Ã¸
  • estate agent
    ºÎµ¿»ê°ü¸®ÀÎ;Áß°³¾÷ÀÚ
  • fiscal agent
    À繫 ´ë¸® ±â°ü;À繫 ´ë¸®ÀÎ
  • forwarding agent
    ¿î¼Û¾÷ÀÚ
  • free agent
    ÀÚÁÖÀûÀÎ ÇàÀ§ÀÚ;ÀÚÀ¯°è¾à ¼±¼ö )
  • general agent
    ÃѴ븮ÀÎ
  • house agent
    º¹´ö¹æ;°¡¿Á ¸Å¸Å ¼Ò°³¾÷ÀÚ
  • inquiry agent
    (¿µ)»ç½Ç ŽÁ¤
  • insurance agent
    º¸Çè´ë¸®Á¡
  • land agent
    ÅäÁö ¸Å¸Å Áß°³¾÷ÀÚ;ÅäÁö °ü¸®ÀÎ
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
ÅëÇÕ°Ë»ö ¿Ï·á